TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: log10 reduction in HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Doppler classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall survival from eligibility
Endpoint domain: Mortality/survival
Primary endpoint: overall survival from administration
Endpoint domain: Mortality/survival
Primary endpoint: ICP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Anxiety Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients With Tissue Deformation in ONH Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Tissue Deformation in Peripapillary Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rim Area (ONH Region) Under Elevated Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rim Area (Peripapillary Region) Under Elevated Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cup Depth (ONH Region) Under Elevated Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive Functions-Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognitive Functions-Executive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain fMRI activation in the left DLPFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood-Brain-Barrier Permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Validation of epidural needle tip position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gastric wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in AUC for ET-1 + BQ-123
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal Muscle Mitochondrial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic sequencing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Birinapant
Endpoint domain: Adverse events/effects
Primary endpoint: HIV Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in glycated haemoglobin (HbA1c) (% point)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in glycated haemoglobin (HbA1c) (mmol/mol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum safe and biologically effective dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Capacity (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Flexion During Deep Knee Bend
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false positive, false negative, true positive, and true negative rates of WFC testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: technical success rate for WFC testing including number of scorable cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of resolution for detecting deletions/duplications by WFC testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: capability and success rate for genotyping single gene mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Energy Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number and grade of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving a Hemoglobin Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days
Endpoint domain: Mortality/survival
Primary endpoint: Total Score of Alzheimer's Disease Assessment Scale - Cognition Subscale (ADAS-COG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of dependent silent spaces (DSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of non-dependent silent spaces (NSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five Year Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Injections With Local Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Autonomic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Psychological Functioning (Wellbeing/Distress)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Turn around time for genomic profiling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: sleep patterns
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in digestive well-being
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With at Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Methamphetamine dependence treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Clinical Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Consumption of Epidural Morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Periodontal attachment gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative muscle dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ADAS-cog
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Generalised Anxiety Disorder-7-item scale (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrent atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrent flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Positive Response to the Solicited Adverse Events Questionnaire
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient related wrist evaluation (PRWE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Survival Outcome
Endpoint domain: Mortality/survival
Primary endpoint: Requirement of Renal Replacement Therapy (RRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence or not of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cancer and Treatment Distress (CTXD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health Care Adherence (HCA)-Cardiometabolic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Modified Physical Performance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of VOA/VOP thalamic DBS
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Vitamin C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil Vitamin C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC Vitamin C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean overall symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete Response rate in untreated PCNSL patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Triathlon CR Active Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of superficial soft tissue lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of screened patients allocated to trials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: glucose absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Romantic Relationship Quality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NIHCQ Vanderbilt assessment scale (Parent)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Natural history of familial carcinoid tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Uptake of the radioligands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with ACR20 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with visual acuity (VA) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfer function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Position of the outer ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: good-quality blastocyst rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Clinical phenotyping of SjD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of biomarker candidates in SjD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue acquisition success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Undetectable PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment referral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency, severity, and duration of hot flash activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term Sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous levels of markers of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of infection/infectivity incidences
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical and laboratory features in patients with anaphylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 60 day readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 90 day readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: rate of stringent complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Prostate Specific Antigen (PSA) Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of avanafil
Endpoint domain: Adverse events/effects
Primary endpoint: Production of IL-10 and IL-6 by B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma drug concentration of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma drug concentration of ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients for Whom Eltrombopag Increases the Platelet Count to > 50,000/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients Who Received Romiplostim and Increased Their Platelet Counts to > 50,000/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oxygen demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Baseline Spontaneous Language
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Efficacy of treatment modality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetics of dark adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dark-adapted retinal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RF hyperacuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major and Overall Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of time in target ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Daily Step Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White Matter Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical Gray Matter Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Deep Gray Matter Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lateral Ventricle Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: External cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bayley Scales of Infant Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Tolerated Dose (MTD) based on adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodialysis outflow vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of completion of MRI scan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response of Langerhans cell histiocytosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-Tocopherol in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gamma-Tocopherol in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malondialdehyde in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to intracranial progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum T50 for CPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD signal in regions of interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Frequency of Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in plasma inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to resolution of vaso-occlusive crisis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of major depressive disorder symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in proportion of generalized anxiety symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of cancers in high-risk individuals and families
Endpoint domain: Mortality/survival
Primary endpoint: component survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Patient reported outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Japanese Orthopaedic Association score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Equivalence of heart sounds data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No Nausea Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Failure rate of the Safe'n'Sound delivery system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in uptake and use of stroke prevention guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yearly TCD screening rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Clostridium Butyricum Miyairi Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Tear Break-up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in pS312-IRS-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Change in pY-IRS-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Niraparib and Abiraterone Acetate After a Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Corus CAD in identifying obstructive CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Semiquantitative assessment of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Complications of Portal Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean rate of change in Physical Health Composite Scale (PCS) scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: One-month Mortality Rate Between the Two Arms
Endpoint domain: Mortality/survival
Primary endpoint: Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change From Baseline in CRP (C-reactive Protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom resolution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in autonomous motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MRI: BOLD Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in brain development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Child cognitive development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning